Emcure Pharmaceuticals Limited (BOM:544210)

Market Cap	264.67B
Revenue (ttm)	84.49B
Net Income (ttm)	7.93B
Shares Out	n/a
EPS (ttm)	41.87
PE Ratio	33.37
Forward PE	25.89
Dividend	3.00 (0.22%)
Ex-Dividend Date	Aug 14, 2025

Volume	5,985
Average Volume	286,580
Open	1,393.65
Previous Close	1,392.90
Day's Range	1,382.10 - 1,429.70
52-Week Range	890.00 - 1,524.85
Beta	n/a
RSI	52.34
Earnings Date	Nov 11, 2025

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 6,731
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544210

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.